Previous 10 | Next 10 |
Progenics Has Again Resorted to False Information and Misleading Innuendo in Seemingly Desperate Attempt to Avoid Accountability and Deprive Stockholders of Chance to Realize Company’s Full Value Velan Purchased Progenics Stock Because of Conviction in Company’s Opportuni...
Flags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan’s Questionable Securities Trading, Governance and Ethical Practices Asks Velan’s Nominees if They Want to Be Associated with These Questionab...
On October 2nd, Lantheus Holdings ( LNTH ) Progenics Pharmaceuticals ( PGNX ), announced an agreement for Lantheus to acquire Progenics in an all-stock transaction. According to the press release, "the transaction has been unanimously approved by the Boards of Directors of both companies." U...
In Velan’s View, Proposed Lantheus Transaction Illustrates Worst Attributes of Progenics Board in Action Believes Current Progenics Board Cannot be Trusted to Represent Best Interests of Stockholders Highlights Company’s Inaccurate and Misleading Statements Related...
Plan Highlights Nominees’ Skill Sets and Expertise that Velan Believes Would Lead to Improvements in Company’s Culture, Operational Execution, Financial Standing, Governance, Leadership and Strategy In Velan’s View, CEO Mark Baker and Current Board Must Be Held Acc...
Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders Urges Shareholders to Sign and Return Progenics’ WHITE...
Believes a Reconstituted Board is Immediately Needed to Reverse Strategic, Operational and Oversight Failures at the Company Urges Stockholders to Continue to Make their Voices Heard Following 2019 Annual Meeting Believes Recently-Announced Lantheus Transaction Massively Underval...
Merger activity increased last week with five new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Dova Pharmaceuticals (DOVA) by Swedish Orphan Biovitrum AB (BIOVF) for $915 million. Under the terms of the agreement, Dova stockholders will ...
Lantheus Holdings' ( LNTH -20.9% ) all-stock deal to buy Progenics Pharmaceuticals ( PGNX +9.8% ) substantially undervalues the target company, says one of Progenics' biggest shareholders. More news on: Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news,...
Believes Company’s Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard Views Progenics’ Potential Value Under Appropriate Leadership to be Substantially Higher Tha...
News, Short Squeeze, Breakout and More Instantly...
Progenics Pharmaceuticals Inc. Company Name:
PGNX Stock Symbol:
NASDAQ Market:
Progenics Pharmaceuticals Inc. Website:
The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...
Biopharma Dynavax Technologies (NASDAQ: DVAX) is one of many companies racing to develop a COVID-19 vaccine. Like many coronavirus-focused companies, Dynavax has seen its shares rise on the ongoing concern related to the pandemic -- in its case, by 50% year to date. While investors may co...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it...